Despite lowering our short-term forecasts, Redeye retains its positive stance on Speqta following the Q1 report. As the integration of Bidbrain/BrightBid is more or less finalized, we expect ARR to accelerate in absolute numbers in late 2024 and beyond. Also, we are positive towards Speqta going for a partnership-based internationalization strategy.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/